A Phase 3 Prospective, Multicenter, Randomized, Double-blind Study of Saroglitazar 4 mg Versus Placebo in Patients with Nonalcoholic Fatty Liver Disease.
Latest Information Update: 04 Mar 2020
At a glance
- Drugs Saroglitazar (Primary)
- Indications Non-alcoholic fatty liver disease
- Focus Therapeutic Use
- Sponsors Cadila Healthcare
- 25 Feb 2020 Planned number of patients changed from 58 to 68.
- 25 Feb 2020 Status changed from recruiting to completed.
- 02 Jan 2018 New trial record